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Obstructive sleep apnea syndrome (OSAS) is considered a low-grade chronic
inflammatory disease. Interleukin-6 (IL-6) is one of the most significant inflammatory
markers and an excellent proxy for the inflammatory/immune system. The present
meta-analysis and meta-regression aimed at comparing plasma and serum levels of
IL-6 between individuals (children and adults) with OSAS and healthy controls. Four
databases, PubMed/Medline, Scopus, Cochrane Library, and Web of Science, were
comprehensively searched to retrieve articles published up to December, 2019, with
no further restrictions. RevMan 5.3 software was used to calculate the crude mean
difference (MD) and 95% confidence interval (CI). The results of funnel plots and
meta-regression were analyzed by the CMA 2.0 software. Sixty-three studies (57 with
adults; six with children) were included in the present meta-analysis. For adults, 37
studies reported significantly higher serum IL-6 levels and 20 reported significantly higher
plasma IL-6 levels for those with OSAS than for healthy controls [pooled MD of 2.89
pg/ml (P < 0.00001) and pooled MD of 2.89 pg/ml (P < 0.00001), respectively]. The
pooled analysis of serum and plasma IL-6 levels in children with OSAS compared with
controls revealed that only theMD of plasma IL-6 levels was significant (MD= 0.84 pg/ml,
P= 0.004). Results of the meta-regression showed that greater age was associated with
higher serum IL-6 levels. Egger’s test revealed a publication bias across the studies for
serum and plasma IL-6 levels (P = 0.00044 and P = 0.01445, respectively). In summary,
the meta-analysis and meta-regression confirmed that, compared to healthy controls,
individuals with OSAS (children and adults) had higher serum/plasma IL-6 levels.
Keywords: obstructive sleep apnea syndrome, interleukin-6, serum, plasma, meta-analysis, pediatric and adult
individuals
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INTRODUCTION
Obstructive sleep apnea syndrome (OSAS) is a complex and
multifactorial disease that includes upper airway obstruction,
chronic intermittent hypoxia, and sleep fragmentation (1). This
disease is associated with insulin resistance (2), obesity (3), and
metabolic syndrome (4), and is a major risk factor for type II
diabetes (5). OSAS is also associated with cardiovascular disease
(6). One study found that the prevalence rate for moderate to
severe OSAS was 23.4% in female individuals, 49.7% in male
individuals, and 70% in individuals with obesity (7). Additionally,
OSAS adds to the development of nonalcoholic fatty liver
disease (8).
In both children and adults with OSAS, the upregulation
has been observed of prototypic inflammatory cytokines such
as interleukin-6 (IL-6), and this in turn increased the nuclear
factor κB (NFκB) pathway activation (9). For these reasons,
OSAS is considered a low-grade chronic inflammatory disease
(10). Repetitive hypoxia and reoxygenation during OSAS lead
to and trigger anti-inflammatory cascades (11). Inflammatory
markers such as IL-6 trigger and enhance vascular inflammation
(12) and contribute to OSAS-related cardiovascular morbidity
(13). Indeed, IL-6 is a multifunctional cytokine with several
biological activities such as the proliferation of T lymphocytes,
the differentiation of B lymphocytes, and the stimulation of
immunoglobulin secretion (14). Remarkably, along with other
bone resorption agents, IL-6 activates bone resorption (15).
Two previous meta-analyses (9, 16) have examined blood IL-
6 levels in individuals with OSAS and combined the results of
serum and plasma blood IL-6 levels. Their results illustrated
an elevated level of this cytokine in individuals with OSAS
when compared to controls. In these meta-analyses with 35
studies in 2015 (16) and 15 studies in 2013 (9), the standard
mean difference (MD) was used to analyze the data while there
were no subgroup analyses based on ethnicity or number of
participants. In addition, the meta-regressions performed in
these two analyses (9, 16) evaluated the correlations between age,
body mass index (BMI), apnea–hypopnea index (AHI) and IL-
6 levels, while the more recent of the two (16) just included
ethnicity in a subgroup analysis, but exclusively in the meta-
regression. Additionally, the earlier meta-analysis (9) did not
include children. To address the limitations of these previous
meta-analyses, we separately analyzed the results for plasma and
serum levels of IL-6 in adults and children with OSAS across
63 studies using MD. We also examined the correlations of age,
BMI, AHI, publication year, and number of participants with IL-
6 level based on a meta-regression. Last, unlike the two previous
meta-analyses, we ran subgroup analyses for ethnicity, number of
participants, BMI, age, and AHI.
Abbreviations: AHI, apnea–hypopnea index; BMI, body mass index; CI,
confidence interval; CPAP, continuous positive air pressure; DALYS, disability-
adjusted life years; EDS, excessive daytime sleepiness; IL-6, interleukin-6; MD,
mean difference; NFκB, nuclear factor κB; NOS, Newcastle–Ottawa Scale; OSAS,
obstructive sleep apnea syndrome; PRISMA, Preferred Reporting Items for
Systematic Reviews and Meta-analyses; SD, standard deviation.
MATERIALS AND METHODS
The review process followed the guidelines in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (17).
Search Strategy
Four databases, PubMed/Medline, Scopus, Cochrane Library,
and Web of Science, were comprehensively searched by one
author (MS) to retrieve articles published up to 1st December,
2019, with no restrictions. The searched terms were (“sleep
apnea” or “obstructive sleep apnea” or “obstructive sleep apnea
syndrome” or “OSA” or “OSAS”) and (“interleukin-6” or “IL-6”
or “interleukin 6”) and (“plasma” or “blood” or “serum”).We also
manually searched for references (original and review articles)
related to these topics.
Eligibility Criteria
Inclusion criteria were the following: (1) studies assessing the
association between plasma or serum IL-6 levels and OSAS
with case–control design without age, sex, or BMI restrictions;
(2) OSAS was defined as AHI > 5 events/h in adults, and
AHI > 1 events/h in children; (3) OSAS was diagnosed with
polysomnography; (4) individuals with OSAS and controls had
no other systematic diseases such as diabetes, neurological
disorders such as multiple sclerosis, or neurodegenerative
disorders such as Alzheimer’s; (5) studies reporting pretreatment
morning serum and/or plasma levels of IL-6 (around 6–10 AM);
(6) studies reporting sufficient data to calculate the MD and 95%
confidence interval (CI) in individuals with OSAS and controls;
and (7) studies with more than 10 cases included as individuals
with OSAS and controls.
Exclusion criteria were the following: (1) studies with
irrelevant or insufficient data or without clinical data; (2)
review articles, conference papers, and book chapters; (3) studies
without a control group; (4) studies reporting controls with AHI
> 5 events/h in adults, and AHI > 1 events/h in children; and (5)
studies reporting data overlapping with other studies.
Study Selection
Two authors (MMI and ME) independently read the titles and
abstracts of the retrieved studies. Then, these two authors selected
the relevant studies, while another author (MS) retrieved the
full texts of the articles and excluded several full texts for the
following reasons: two were meta-analyses; five were reviews; two
were letter to editor studies; 25 had no control condition, or the
control group was selected as AHI > 5 events/h in adults and
AHI > 1 events/h in children; one had <10 cases included in
both groups; six had no relevant data; one had duplicated data
with another study; two did not report baseline IL-6 levels; one
reported polymorphisms of IL-6; one reported high sensitivity
IL-6 levels; three did not report morning level of IL-6; and one
reported the level of IL-6 in exhaled breath condensate. Where
two studies had overlapping data, we selected the study with the
more recent publication year.
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Data Extraction
Two authors (SB and MS) independently extracted the data
from each study included in the meta-analysis. If there was a
disagreement between the two authors, a third author (MMI)
helped to reach a final decision. The data extracted for the meta-
analysis included basic information including the first author,
FIGURE 1 | Flowchart of the study.
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publication year, country of study, ethnicity of participants,
age, BMI, and AHI of both groups, and mean and standard
deviation (SD) of IL-6 levels in plasma and serum. Since
some studies considered patients with mild OSAS (AHI, 1–
5 events/h) as a control group condition, and since we had
used this protocol for other studies, reporting the quality of
studies as for usual case–control studies did not seem to
be reasonable.
Quality Assessment
One author (MS) assessed the quality of the studies included in
the meta-analysis using the Newcastle–Ottawa Scale (NOS); the
total possible score for each study was 9 (18).
Statistical Analyses
The data were analyzed by one author. Review Manager
5.3 software (RevMan 5.3) was used to calculate the crude
MD and 95% CI, which evaluated the significance of the
pooled MD by Z test. Heterogeneity was assessed across the
studies using both Cochran Q (19) and I2 metrics with scores
ranging from 0 to 100% (20). In addition, in case of values
of Pheterogeneity (Ph < 0.1) and I
2
> 50%, this indicated a
significant heterogeneity, and in this case, analysis of the random
effect model was performed to evaluate the pooled MD and
95% CI values. Otherwise, we used the analysis by the fixed
effect model.
The results of Begg’s and Egger’s tests were analyzed by
the Comprehensive Meta-Analysis version 2.0 software (CMA
2.0). Begg’s funnel plot shows the standard error (SE) of the
log (MD), and the precision of each study is plotted against
its log (MD) (21). Egger’s test shows the linear regression
between the precision of the studies and the standardized
effect (22). Subgroup analyses were performed based on
ethnicity, AHI, BMI, and sample size. Sensitivity analyses,
namely, the “cumulative analysis” and “one study removed,”
were used to estimate the consistency/stability of the results.
A P value (two-tailed) of <0.05 was taken to indicate a
significant difference. Meta-regression is a quantitative method
used in meta-analyses to estimate the impact of moderator
variables on study effect size. The trim-and-fill method was
used to estimate potentially missing studies due to publication
bias in the funnel plot and to adjust the overall effect
estimate (23).
Some studies reported the values for IL-6 in standard
errors (SE); SEs were transformed into standard deviations
(SD), (SE = SD/
√
N; N = number of individuals). Some
studies reported median and interquartile values, which were
transformed into mean and SD (24). The IL-6 levels in the
serum and plasma were reported in picograms per milliliter




A total of 892 records were identified in the four
electronic databases. Figure 1 sets out the literature
selection of these studies. After excluding duplications and
irrelevant records, 113 full-text articles met the eligibility
criteria. After evaluating the full texts, 50 articles were
excluded as mentioned in Study Selection. At the end,
63 studies were included in the present meta-analysis
(12, 26–87).
Basic Characteristics of the Studies
As shown in Table 1, of the 63 studies retained for analysis, 14
were conducted in China (27, 39, 46, 50, 51, 54, 55, 58, 65, 73,
77, 81, 82, 86), eight in the USA (26, 28, 34, 38, 56, 76, 78,
83), six in Greece (37, 43, 47, 49, 58, 64), six in Japan (29–
31, 41, 42, 44), six in Turkey (12, 57, 62, 67, 68, 70), three
in Italy (59, 63, 87), 3 in Brazil (45, 53, 72), three in Spain
(36, 60, 71), two in Sweden (66, 84), two in India (79, 85), one
in Ireland (32), one in Germany (35), one in Thailand (40), one
in Finland (48), one in Canada (52), one in the UK (74), one
in Croatia (80), one in Australia (33), one in Taiwan (69), and
one in Belgium (75). With regard to ethnicity, 28 studies were
performed with Caucasians (12, 32, 35–37, 43, 47–49, 57, 59–
64, 66–68, 70, 71, 74, 75, 79, 80, 84, 85, 87), 22 with Asians
(27, 29–31, 39–42, 44, 46, 50, 51, 54, 55, 58, 65, 69, 73, 77,
81, 82, 86), and 13 with mixed ethnicities (26, 28, 33, 34, 38,
45, 52, 53, 56, 72, 76, 78, 83). Of the 63 studies, 40 reported
IL-6 levels in serum (12, 28, 30–34, 37, 39, 40, 44, 46, 47, 49–
57, 62, 63, 65–68, 70, 72–77, 79, 81, 82, 85, 87), and 23 reported
IL-6 levels in plasma (26, 27, 29, 35, 36, 38, 41–43, 45, 48, 55, 58–
61, 64, 69, 71, 78, 80, 83, 84). Six studies included children
(33, 38, 39, 60, 69, 75). Other characteristics of individuals with
OSAS and controls (number of cases, age, BMI, and AHI) are
shown in Figure 1.
Meta-Analysis
Serum IL-6 Levels in Individuals With Obstructive
Sleep Apnea Syndrome
Thirty-nine studies of serum IL-6 levels in adults included 2,558
individuals with OSAS and 1,897 controls (Figure 2). The pooled
analysis of individuals with OSAS compared to controls yielded
an MD of 2.89 pg/ml [95% CI: 2.54, 3.23; P < 0.00001; I2 = 99%
(Ph < 0.00001)]. Thus, serum levels of IL-6 were significantly
higher in individuals with OSAS than in controls.
Plasma IL-6 Levels in Individuals With Obstructive
Sleep Apnea Syndrome
Figure 3 shows the results of 22 studies reporting plasma IL-6
levels adults; plasma IL-6 levels of 974 individuals with OSAS
were compared to the levels of 692 controls. The pooled analysis
comparing these two groups showed that the MD was 2.89 pg/ml
[95%CI: 1.94, 3.85; P< 0.00001; I2 = 99% (Ph < 0.00001)]. Thus,
plasma IL-6 levels of individuals with OSAS were significantly
higher than those of controls.
Serum IL-6 Levels in Children With Obstructive Sleep
Apnea Syndrome
Figure 4 illustrates the results of three studies on serum IL-6
levels of 144 children with OSAS compared to 274 controls. The
pooled analysis of the comparison between these groups revealed




































TABLE 1 | Characteristics of studies included in the meta-analysis (n = 63).
First author, year Country Ethnicity No. of
OSAS/control
OSAS patients Controls Sample
Age (years) BMI (kg/m2) AHI
(events/h)
Age (years) BMI (kg/m2) AHI
(events/h)
ADULTS
Vgontzas, 1997 (26) USA Mixed 12/10 40.9 ± 2.2 40.5 ± 3.2 63.7 ± 10.3 24.1 ± 0.8 24.6 ± 0.7 0 ± 0 Plasma
Huiguo, 2000 (27) China Asian 22/16 47.4 ± 13.6 27.6 ± 3.3 44.0 ± 21.0 47.6 ± 14.7 23.1 ± 3 4.29 ± 2.16 Plasma
Roytblat, 2000 (28) USA Mixed 11/12 39.5 ± 5.0 38.3 ± 8.0 ≥5 32.8 ± 8.2 21.0 ± 5.3 <5 Serum
Teramoto, 2003 (29) Japan Asian 40/40 Adult NR ≥5 Adult NR <5 Plasma
Yokoe, 2003 (30) Japan Asian 26/14 52.5 ± 5.7 28.4 ± 3.5 33.7 ± 24.5 48.8 ± 3.0 27.6 ± 0.5 2.8 ± 0.2 Serum
Ciftci, 2004 (12) Turkey Caucasian 43/22 49.6 ± 9.1 31.9 ± 4.1 33.2 ± 5.0 47.2 ± 10.3 31.03 ± 3.1 1.55 ± 0.96 Serum
Imagawa, 2004 (31) Japan Asian 117/46 Adult 27.7 ± 4.4 ≥5 Adult 22.9 ± 2.9 <5 Serum
Ryan, 2006 (32) Ireland Caucasian 66/30 42.5 ± 8.5 32.5 ± 4.8 35.0 ± 13.9 41 ± 8 30.7 ± 3.1 1.2 ± 1.0 Serum
de la Peña Bravo, 2007 (34) USA Mixed 50/20 51.7 ± 1.9 33.2 ± 1.7 51.3 ± 4.2 47.4 ± 1.2 28.4 ± 0.6 2.5 ± 0.5 Serum
Harsch, 2007 ((35) Germany Caucasian 19/20 59.0 ± 2.0 34.4 ± 1.4 ≥5 53.0 ± 2.0 31.6 ± 1.0 <5 Plasma
Arias, 2008 (36) Spain Caucasian 30/15 52.0 ± 13.0 30.5 ± 4.0 43.8 ± 27.0 48.0 ± 10.0 28.7 ± 4.7 3.7 ± 3.3 Plasma
Constantinidis, 2008 (37) Greece Caucasian 24/27 45.1 ± 8.2 ≥25 23.3 ± 3.6 45.1 ± 8.2 ≥25 3.5 ± 0.4 Serum
Li, 2008 (40) Thailand Asian 68/22 45.5 ± 11.3 27.7 ± 4.6 31.4 ± 28.6 43 ± 9 23.3 ± 2.0 2.9 ± 1.3 Serum
Takahashi, 2008 (41) Japan Asian 41/12 49.8 ± 10 29.4 ± 4.2 ≥5 46.7 ± 11.2 25.7 ± 4.1 <5 Plasma
Tomiyama, 2008 (42) Japan Asian 50/15 51.4 ± 13.0 26.9 ± 4.2 42.7 ± 27.9 53.0 ± 10.0 24.3 ± 2.5 <5 Plasma
Vgontzas, 2008 (43) Greece Caucasian 16/28 48.1 ± 5.6 37.5 ± 4.7 53.3±7.0 48.1 ± 10.6 30.8 ± 5.2 2.1 ± 0.8 Plasma
Yamamoto, 2008 (44) Japan Asian 31/10 49.0 ± 2.0 28.0 ± 1.0 ≥5 46.0 ± 6.0 27.0 ± 2.0 <5 Serum
Carneiro, 2009 (45) Brazil Mixed 16/13 40.1 ± 2.8 46.9±2.0 65.7 ± 9.9 38.8 ± 3.3 42.8 ± 1.3 3.2 ± 0.5 Plasma
Li, 2009 (46) China Asian 68/22 45.3 ± 11.1 20.7 ± 10.1 38.9 ± 26.5 43.0 ± 93.0 23.3 ± 2.0 2.9 ± 1.3 Serum
Thomopoulos, 2009 (47) Greece Caucasian 62/70 48.1 ± 7.6 31.9 ± 4.9 31.6 ± 2.0 48.1 ± 3.9 32.1 ± 3.0 0.4 ± 4.0 Serum
Sahlman, 2010 (48) Finland Caucasian 84/40 50.4 ± 9.3 32.5 ± 3.3 9.6 ± 2.9 45.6 ± 11.5 31.5 ± 3.5 1.9 ± 1.4 Plasma
Steiropoulos, 2010 (49) Greece Caucasian 38/23 45.5 ± 10.5 36.4 ± 7.4 61.0 ± 27.0 43.7 ± 6.7 34.5 ± 3.7 5.3 ± 3.2 Serum
Ye, 2010 (50) China Asian 127/52 45.3 ± 11.4 26.2 ± 3.7 36.5 ± 25.7 45.0 ± 10.0 26.0 ± 3.2 2.0 ± 1.4 Serum
Liu, 2011(51) China Asian 78/20 45.2 ± 7.3 27.9 ± 3.1 46.3 ± 9.2 43.5 ± 8.3 26.1 ± 2.4 <5 Serum
Fornadi, 2012 (52) Canada Mixed 25/75 54.0 ± 12.0 29.0 ± 5.0 ≥5 50.0 ± 13.0 26.0 ± 5.0 <5 Serum
Medeiros, 2012 (53) Brazil Mixed 50/15 62.3 ± 7.8 25.5 ± 4.0 ≥5 62.50±8.4 25.8 ± 4.0 <5 Serum
Qian, 2012 (54) China Asian 70/40 45.8 ± 8.2 28.9 ± 2.3 ≥5 46.3 ± 8.1 24.1 ± 2.3 <5 Serum
Ye, 2012 (55) China Asian 44/20 46.43 ±
18.22




26.90 ± 4.25 2.26 ± 1.30 Plasma
Hargens, 2013 (56) USA Mixed 12/33 22.8 ± 0.8 32.4 ± 1.0 25.4 ± 5.4 21.9 ± 0.6 29.3 ± 0.5 2.1 ± 0.3 Serum
Kurt, 2013 (57) Turkey Caucasian 48/37 48.3 ± 12.3 NR ≥5 43.1 ± 14.1 NR <5 Serum
Yang, 2013 (58) China Asian 50/25 53.5 ± 6.9 27.4 ± 2.9 24.5 ± 15.9 53.0 ± 7.0 26.27 ± 1.9 3.0 ± 1.0 Plasma

















































































TABLE 1 | Continued
First author, year Country Ethnicity No. of
OSAS/control
OSAS patients Controls Sample
Age (years) BMI (kg/m2) AHI
(events/h)
Age (years) BMI (kg/m2) AHI
(events/h)
Kritikou, 2014 (61) Greece Caucasian 38/39 55.7 ± 6.6 28.7 ± 3.3 37.5 ± 21.0 53.8 ± 6.2 27.3 ± 3.5 2.3 ± 1.9 Plasma
Unuvar Dogan, 2014 (62) Turkey Caucasian 33/24 45.3 ± 8.5 31.0 ± 1.7 47.2 ± 23.2 40.5 ± 9.5 30.7 ± 1.5 3.6 ± 1.8 Serum
De, 2015 (63) Italy Caucasian 26/24 41.8 ± 7.4 33.0 ± 5.2 26.15 ± 12.1 43.7 ± 8.2 30.8 ± 4.3 1.65 ± 0.9 Serum
Gaines, 2015 (64) Greece Caucasian 82/38 54.9 ± 5.8 29.2 ± 3.3 22.6 ± 15.0 54.2 ± 5.8 27.6 ± 3.7 2.0 ± 15.0 Plasma
Hui, 2015 (65) China Asian 35/20 47.6 ± 6.6 27.3 ± 4.4 ≥5 25.1 ± 5.3 40.5 ± 4.9 <5 Serum
Ulasli, 2015 (67) Turkey Caucasian 62/20 51.7 ± 10.2 32.4 ± 5.6 26.5 ± 18.5 45.3 ± 14 30.4 ± 8 2.2 ± 0.93 Serum
Thunstrom, 2015 (66) Sweden Caucasian 344/95 61.9 ± 9.2 28.9 ± 4.0 29.7 ± 14.6 61.4 ± 9.5 25.2 ± 2.5 3.1 ± 1.3 Serum
Dogan, 2016 (68) Turkey Caucasian 39/12 40.7 ± 10.75 29.26 ± 4.12 ≥5 40.0 ± 11.7 27.29 ± 2.93 <5 Serum
Nizam, 2016 (70) Turkey Caucasian 39/13 47.3 ± 10.4 33.2 ± 56.4 45.6 ± 20.7 43.23 ± 9.08 31.71 ± 4.56 2.64 ± 1.82 Serum
Vicente, 2016 (71) Spain Caucasian 89/26 45.33 ±
14.81
30.03 ± 5.04 28 ± 23.70 45 ± 11.11 28.7 ± 4.37 1.9 ± 2.7 Plasma
Hirotsu, 2017 (72) Brazil Mixed 339/682 50.8 ± 13.2 29.6 ± 5.8 19.3 ± 9.44 38.2 ± 12.7 25.4 ± 3.8 2.5 ± 10.4 Serum
Kong, 2017 (73) China Asian 82/30 45.6 ± 8.8 27.7 ± 4.6 ≥5 45.7 ± 6.6 27.6 ± 3.6 <5 Serum
Thorn, 2017 (74) UK Caucasian 16/14 59 ± 13 32.7 ± 4.0 30 ± 18 58 ± 7 30.6 ± 2.7 <5 Serum
Weingarten, 2017 (76) USA Mixed 11/8 38.7 ± 10.5 47.3 ± 14.8 25.1 ± 17.8 33.6 ± 5.1 25.5 ± 10.9 1.8 ± 1.0 Serum
Zhang, 2017 (77) China Asian 50/52 79.4 NR ≥5 77.1 NR <5 Serum
Al-Terki, 2018 (78) USA Mixed 52/22 40.3 ± 1.6 29.5 ± 0.7 22.9 ± 17.9 39.6 ± 2.2 28.5 ± 0.9 2.5 ± 1.6 Plasma
Bhatt, 2018 (79) India Caucasian 171/69 44.6 ± 9.1 33.1 ± 7.6 ≥5 40.0 ± 9.8 30.1 ± 8.4 <5 Serum
Bozic, 2018 (80) Croatia Caucasian 50/25 53.0 ± 11.9 28.9 ± 2.7 35.0 ± 11.0 52.5 ± 10.2 27.8 ± 2.2 <5 Plasma
Kong, 2018 (81) China Asian 50/40 54.34 ±
14.38
26.86 ± 3.12 37.34 ±
19.02
50.42 ± 8.35 22.26 ± 3.54 3.31 ± 1.09 Serum
Lu, 2018 (82) China Asian 35/22 48.63 ± 1.80 28.21 ± 0.51 ≥5 49.04 ± 2.27 26.01 ± 0.65 <5 Serum
Motamedi, 2018 (83) USA Mixed 50/24 34.9 ± 8.0 30.8 ± 4.2 18.4 ± 13.1 30.9 ± 7.77 28.6 ± 3.81 2.12 ± 1.3 Plasma
Sundbom, 2018 (84) Sweden Caucasian 109/224 55.6 ± 8.8 28.2 ± 4.8 25.4 ± 2.1 47.7 ± 11.3 25.4 ± 4.1 3.7 ± 0.6 Plasma
Bhatt, 2019 (85) India Caucasian 47/25 44.2 ± 9.1 32.5 ± 6.9 13.5 ± 6.4 28.5 ± 8.6 41 ± 8.5 2.3 ± 1.1 Serum
Tang, 2019 (86) China Asian 120/127 48.88 ± 9.76 26.86 ± 3.12 39.00 ±
18.38
47.37 ± 9.12 22.46 ± 3.29 3.31 ± 1.09 Serum
Galati, 2020 (87) Italy Caucasian 45/30 53.9 ± 11.6 28 ± 2.2 ≥5 55 ± 5.8 26.3 ± 1.8 <5 Serum
CHILDREN
Tam, 2006 (33)
Australia Mixed 44/69 7.3 ± 3.7 19.4 ± 5.5 5.3 ± 6.5 7.6 ± 4.0 17.9 ± 3.9 0 ± 0 Serum
Gozal, 2008 (38) USA Mixed 20/20 6.5 ± 0.6 17.3 ± 0.6 ≥5 6.4 ± 0.7 17.1 ± 0.5 0 ± 0 Plasma
Li, 2008 (39) China Asian 47/95 11.1 ± 1.27 NR 14.1 ± 8.0 10.7 ± 1.3 NR 0.7 ± 0.6 Serum
Gileles-Hillel, 2014 (60) Spain Caucasian 75/129 10.4 ± 2.8 28.0 ± 4.6 14.2 ± 9.0 11.0 ± 2.4 27.9 ± 4.1 0.6 ± 0.6 Plasma
Huang, 2016 (69) Taiwan Asian 47/32 7.84 ± 0.56 16.95 ± 0.47 9.13 ± 1.67 7.02 ± 0.65 16.55 ± 0.58 0.37 ± 0.06 Plasma
Van Eyck, 2017 (75) Belgium Caucasian 53/111 11.5 ± 2.75 NR 20.53 ±
15.98
12 ± 2.75 NR 0.72 ± 0.47 Serum
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FIGURE 2 | Forest plot of random-effects analysis of serum interleukin-6 levels in adults. The diamond shape indicates the pooled mean difference (MD). Each black
box represents a point estimate of each study and also gives a representation of the study size (the bigger the box, the more participants in the study). A horizontal line
representing the 95% confidence intervals (CIs) of the study result, with each end of the line representing the boundaries of CI. SD, standard deviation; OSAS,
obstructive sleep apnea syndrome.
that the MD was −0.20 pg/ml [95% CI: −0.82, 0.42; P = 0.52; I2
= 83% (Ph = 0.01)]. Thus, serum IL-6 levels did not significantly
differ between children with OSAS and controls.
Plasma IL-6 Levels in Pediatric Participants With
Obstructive Sleep Apnea Syndrome
Five studies of plasma IL-6 levels in children included 142
children with OSAS and 181 controls (see Figure 5). The pooled
analysis in this case revealed that the MD was 0.84 pg/ml [95%
CI: 0.27, 1.41; P= 0.004; I2 = 72% (Ph = 0.03)]. The plasma IL-6
levels of children with OSAS were thus significantly higher than
those of the controls.
Subgroup Analysis of Serum IL-6 Levels
Ethnicity
Subgroup analyses of serum IL-6 levels in adults are reported in
Table 2. The pooled analysis showed that for those with OSAS,
serum IL-6 levels in Caucasian (MD= 0.51 pg/ml, P < 0.00001),
Asian (MD = 11.52 pg/ml, P < 0.00001) and mixed (MD = 2.49
pg/ml, P = 0.004) ethnicities were significantly higher than the
serum IL-6 levels of the respective controls.
Body Mass Index
Compared to healthy controls, the pooled MD of serum
IL-6 levels of individuals with OSAS was significantly higher
irrespective of their BMI: mean BMI > 30 (MD = 1.07 pg/ml,
P < 0.00001); mean BMI ≤ 30 kg/m2 (MD = 10.59 pg/ml,
P < 0.00001).
Compared to OSAS individuals with mean BMI > 30 kg/m2,
OSAS individuals with BMI ≤ 30 kg/m2 had the pooled MD in
serum IL-6 levels 9.9 times higher than controls.
Serum IL-6 levels were higher in participants with OSAS,
irrespective of whether the BMI of controls was>30 (pooled MD
of serum IL-6 levels was 0.47 pg/ml, P = 0.001), or ≤30 kg/m2
(pooled MD of serum IL-6 levels was 9.55 pg/ml, P < 0.00001).
For participants with OSAS, serum IL-6 levels were 20.3 times
higher in controls with a BMI < 30 kg/m2 when compared to
controls with a mean BMI > 30 kg/m2.
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FIGURE 3 | Forest plot of random-effects analysis of plasma interleukin-6 levels in adults. The diamond shape indicates the pooled mean difference (MD). Each black
box represents a point estimate of each study and also gives a representation of the study size (the bigger the box, the more participants in the study). A horizontal line
representing the 95% confidence intervals (CIs) of the study result, with each end of the line representing the boundaries of CI. SD, standard deviation; OSAS,
obstructive sleep apnea syndrome.
FIGURE 4 | Forest plot of random-effects analysis of serum interleukin-6 levels in children. The diamond shape indicates the pooled mean difference (MD). Each black
box represents a point estimate of each study and also gives a representation of the study size (the bigger the box, the more participants in the study). A horizontal line
representing the 95% confidence intervals (CIs) of the study result, with each end of the line representing the boundaries of CI. SD, standard deviation; OSAS,
obstructive sleep apnea syndrome.
FIGURE 5 | Forest plot of random-effects analysis of plasma interleukin-6 levels in children. The diamond shape indicates the pooled mean difference (MD). Each
black box represents a point estimate of each study and also gives a representation of the study size (the bigger the box, the more participants in the study). A
horizontal line representing the 95% confidence intervals (CIs) of the study result, with each end of the line representing the boundaries of CI. SD, standard deviation;
OSAS, obstructive sleep apnea syndrome.
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TABLE 2 | Subgroup analysis for serum and plasma levels of inteleukin-6 in adults.
Subgroup analysis of serum level (n) MD (95% CI), P-value, I2 (%), Ph Subgroup analysis of plasma level (n) MD (95% CI), P-value, I
2 (%), Ph
Overall (37) 2.89 (2.54, 3.24), <0.00001, 99,
<0.00001
Overall (20) 2.89 (1.94, 3.85), <0.00001, 99,
<0.00001
Ethnicity Ethnicity
Caucasian (16) 0.51 (0.29, 0.73), <0.00001, 97,
<0.00001
Caucasian (10) 0.75 (−0.06, 1.57), 0.07, 98,
<0.00001
Asian (14) 11.52 (10.20, 12.83), <0.00001,
100, <0.00001
Asian (6) 8.93 (4.87, 12.99), <0.0001, 100,
<0.00001
Mixed (7) 2.49 (0.80, 4.17), 0.004, 96,
<0.00001
Mixed (4) 0.75 (0.21, 1.29), 0.006, 45, 0.14
Mean BMI of OSAS patients, kg/m2 Mean BMI of OSAS patients, kg/m2
>30 (15) 1.07 (0.63, 1.50), <0.00001, 97,
<0.00001
>30 (8) 0.96 (−1.16, 3.07), 0.38, 98,
<0.00001
≤30 (19) 10.59 (8.64, 12.53), <0.00001, 100,
<0.00001
≤30 (11) 4.20 (2.95, 5.46), <0.00001, 99,
<0.00001
Mean BMI of controls, kg/m2 Mean BMI of controls, kg/m2
>30 (12) 0.47 (0.19, 0.76), 0.001, 89,
<0.00001
>30 (4) 1.69 (−4.61, 8.00), 0.60, 99,
<0.00001
≤30 (22) 9.55 (7.85, 11.25), <0.00001, 100,
<0.00001
≤30 (15) 3.05 (2.096, 4.01), <0.00001, 99,
<0.00001
Total number of participants Total number of participants
>100 (9) 9.52 (2.94, 16.11), 0.005, 100,
<0.00001
>100 (5) 0.42 (0.00, 0.84), 0.05, 92, <0.00001
≤100 (28) 1.43 (1.14, 1.71), <0.00001, 99,
<0.00001
≤100 (15) 4.56 (2.51, 6.61), <0.0001, 99,
<0.00001
Mean AHI of OSAS patients, events/h Mean AHI of OSAS patients, events/h
>30 (14) 6.13 (5.31, 6.95), <0.00001, 100,
<0.00001
>30 (9) 5.87 (3.37, 8.37), <0.00001, 99,
<0.00001
≤30 (10) 1.93 (1.20, 2.66), <0.00001, 98,
<0.000101
≤30 (7) 0.43 (0.10, 0.75), 0.01, 82, <0.00001
BMI, body mass index; CI, confidence interval; OSAS, obstructive sleep apnea syndrome; MD, mean difference; Ph, Pheterogeneity .
Bold numbers show statistically significant value (P < 0.05).
Sample Sizes
With regard to the number of participants in each study,
those with more than 100 cases across OSAS and control
groups had a pooled MD of serum IL-6 levels of 9.52
pg/ml (P = 0.005); the studies with ≤100 cases across
the two groups had pooled MD of 1.43 pg/ml (P <
0.00001). In other words, serum IL-6 levels in studies
with more than 100 cases were 6.6 times higher than the
levels of studies including ≤100 cases across OSAS and
control groups.
Apnea–Hypopnea Index
Studies with a mean AHI > 30 events/h in participants
with OSAS showed that the pooled MD of their serum IL-
6 levels was 6.13 pg/ml (P < 0.00001), compared to controls.
Studies including participants with OSAS with a mean AHI
≤ 30 events/h showed that the pooled MD between OSAS
individuals and controls was 1.93 pg/ml (P < 0.00001). Thus,
serum IL-6 levels in studies with mean AHI > 30 events/h
in participants with OSAS were 3.2 times higher than serum
IL-6 levels in studies including OSAS patients with mean
AHI ≤ 30 events/h.
Subgroup Analysis of Plasma IL-6 Levels
Ethnicity
The subgroup analysis of the pooled MD for plasma IL-6
levels in Asian (MD = 8.93 pg/ml, P = 0.0001) and mixed
ethnicity (MD = 0.75 pg/ml, P = 0.006) participants with
OSAS showed significant differences with the respective controls.
The result showed that plasma IL-6 levels of Asians were
11.9 times higher than the plasma IL-6 levels of those of
mixed ethnicity with OSAS. Plasma IL-6 levels of Asians did
not statistically significantly differ from the plasma level of a
Caucasian ethnicity.
Body Mass Index
In studies including participants with a mean BMI ≤ 30 kg/m2,
the pooled MD comparing plasma IL-6 levels in participants
with OSAS with plasma IL-6 levels of controls was significant
(MD = 4.20 pg/ml, P < 0.00001). The pooled MD was
also significant for plasma IL-6 levels in studies including
a mean BMI of controls ≤30 (MD = 3.05 pg/ml, P <
0.00001). In contrast, there was no significant difference between
participants with or without OSAS when the BMI of OSAS
patients >30 kg/m2.
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TABLE 3 | Subgroup analysis for serum and plasma levels of inteleukin-6 in adult Caucasians.
Subgroup analysis of serum level (n) MD (95% CI), P-value, I2 (%), Ph Subgroup analysis of plasma level (n) MD (95% CI), P-value, I
2 (%), Ph
Overall (16) 0.51 (0.29, 0.73), <0.00001, 97,
<0.00001
Overall (10) 0.75 (−0.06, 1.57), 0.07, 98,
<0.00001
Mean BMI of OSAS patients, kg/m2 Mean BMI of OSAS patients, kg/m2
>30 (11) 0.35 (0.09, 0.62), 0.008, 87,
<0.00001
>30 (5) 0.46 (0.01, 0.91), 0.05, 92, <0.00001
≤30 (3) 2.54 (0.90, 4.19), 0.002, 92,
<0.00001
≤30 (5) 0.89 (0.27, 1.50), 0.005, 96,
<0.00001
Mean BMI of controls, kg/m2 Mean BMI of controls, kg/m2
>30 (11) 0.35 (0.09, 0.62), 0.008, 87,
<0.00001
>30 (3) 2.26 (−5.67, 10.20), 0.58, 99,
<0.00001
≤30 (3) 2.54 (0.90, 4.19), 0.002, 92,
<0.00001
≤30 (7) 0.71 (0.19, 1.23), 0.007, 95,
<0.00001
Total number of participants Total number of participants
>100 (3) 1.81 (0.75, 2.87), 0.0008, 78, 0.01 >100 (4) 0.56 (−0.28, 1.41), 0.19, 93,
<0.00001
≤100 (13) 0.34 (0.11, 0.56), 0.003, 97,
<0.00001
≤100 (6) 1.14 (−1.72, 4.00), 0.44, 99,
<0.00001
Mean AHI of OSAS patients, events/h Mean AHI of OSAS patients, events/h
>30 (6) 0.23 (−0.11, 0.57), 0.18, 77, 0.0006 >30 (5) 1.48 (1.26, 1.70), <0.00001, 26, 0.25
≤30 (6) 0.61 (0.33, 0.88), <0.0001, 88,
<0.0001
≤30 (4) 0.19 (0.16, 0.23), <0.00001, 24, 0.27
BMI, body mass index; CI, confidence interval; OSAS, obstructive sleep apnea syndrome; MD, mean difference; Ph, Pheterogeneity .
Bold numbers show statistically significant value (P < 0.05).
Sample Size
The pooled MD for plasma IL-6 levels in studies where the
total number of participants ≤100 was significant (MD =
4.56 pg/ml, P < 0.0001); plasma IL-6 levels in those with
OSAS was significantly higher than controls. In contrast,
there was no significant difference between participants with
OSAS and controls in the studies where the total number of
participants >100.
Apnea–Hypopnea Index
Compared to controls, for participants with OSAS, the plasma
IL-6 levels were significantly higher in studies wheremeanAHI of
OSAS participants>30 events/h (MD= 5.87 pg/ml, P< 0.00001)
but lower in studies where the AHI ≤30 events/h (MD = 0.43
pg/ml, P = 0.01). The MD in plasma IL-6 levels in studies where
mean AHI of OSAS participants >30 events/h was 13.6 times
greater than in studies where this mean AHI ≤ 30 events/h.
Serum IL-6 Levels in Adult Caucasians
Body Mass Index
In a further subgroup analysis, the pooled MD comparing serum
and plasma IL-6 levels in OSAS adult Caucasians and controls
was investigated (Table 3). The pooled MDs in those studies
with OSAS participants with a mean BMI > 30 kg/m2 (MD =
0.35 pg/ml, P = 0.008) and those where the BMI ≤ 30 kg/m2
(MD = 2.54 pg/ml, P = 0.002) were significant when compared
to controls’ serum IL-6 levels. This pattern was independent of
controls’ BMI, whether higher or lower than 30 kg/m2. Thus,
serum IL-6 level in studies where OSAS participants and controls
had a BMI≤ 30 kg/m2 was 7.3 times higher than serum IL-6 level
in studies where OSAS participants and controls had a BMI >
30 kg/m2.
Sample Sizes
With regard to studies of Caucasians, in those studies with more
than 100 cases with or without OSAS, the pooled MD for serum
IL-6 level was 1.81 pg/ml (P = 0.0008). In the studies with ≤100
cases with or without OSAS, the pooled MD for serum IL-6 level
was 0.34 pg/ml (P < 0.003). In other words, serum IL-6 levels
in studies with sample sizes >100 were higher than the levels in
studies with sample sizes ≤100.
Apnea–Hypopnea Index
For Caucasian samples, the studies with a mean AHI ≤ 30
events/h in participants with OSAS showed that the pooled MD
of serum IL-6 levels was 0.61 pg/mL (P < 0.0001). However,
serum IL-6 levels did not differ between OSAS participants and
controls where AHI was >30 events/h.
Plasma IL-6 Levels in Adult Caucasians
Body Mass Index
The pooled MD was significant for plasma IL-6 levels in studies
with Caucasian participants with OSAS and with a mean BMI ≤
30 kg/m2 (MD = 0.89 pg/ml, P = 0.005) were compared with
controls, but there was no significant difference in those studies
where the OSAS participants had a mean BMI > 30 kg/m2.
Sample Size
The pooled MD of plasma IL-6 levels was independent of sample
size (samples smaller or larger than 100 per group).
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Apnea–Hypopnea Index
The pooled MD for plasma IL-6 levels was significantly higher
(7.8 times) in Caucasians with OSAS and a mean AHI > 30
events/h (MD = 1.48 pg/ml; P = 0.002) when compared to
those with OSAS and a mean AHI ≤ 30 events/h (MD = 0.19
pg/ml; P < 0.00001).
TABLE 4 | Subgroup analysis for serum level of inteleukin-6 in adult Asians.
Subgroup analysis of serum
level (n)
MD (95% CI), P-value, I2 (%),
Ph
Overall (14) 11.52 (10.20, 12.83), <0.00001,
100, <0.00001
Mean BMI of OSAS patients, kg/m2
>30 (0) NA
≤30 (14) 11.52 (10.20, 12.83), <0.00001,
100, <0.00001
Mean BMI of controls, kg/m2
>30 (1) 4.03 (2.38, 5.68), <0.00001
≤30 (13) 12.30 (10.92, 13.68), <0.00001,
100, <0.00001
Total number of participants
>100 (5) 15.86 (−11.58, 43.30), 0.26,
100, <0.00001
≤100 (9) 4.85 (3.96, 5.74), <0.00001, 99,
<0.00001
Mean AHI of OSAS patients, events/h
>30 (7) 18.16 (10.17, 26.15), <0.0001,
100, <0.00001
≤30 (0) NA
BMI, body mass index; CI, confidence interval; OSAS, obstructive sleep apnea syndrome;
MD, mean difference; NA, not available; Ph, Pheterogeneity .
Bold numbers show statistically significant value (P < 0.05).
Serum Levels of IL-6 in Adult Asian
Participants With and Without OSAS
A subgroup analysis for serum IL-6 levels in adult Asians is
reported in Table 4. There were significant differences between
individuals with OSAS and controls for those studies reporting
for the OSAS group amean BMI≤ 30 kg/m2 (MD= 11.52 pg/ml,
P < 0.00001), a mean BMI of controls >30 kg/m2 (MD = 4.03
pg/ml, P < 0.00001), a mean BMI of controls≤30 kg/m2 (MD=
12.30 pg/ml, P < 0.00001), a total sample size≤ 100 (MD= 4.85
pg/ml, P < 0.00001), and mean AHI of OSAS individuals >30
events/h (MD= 18.16 pg/ml, P < 0.0001).
Mean BMI of OSAS Patients >30 kg/m2
Table 5 reports the subgroup analysis for serum and plasma
IL-6 levels in adults where the mean BMI of those with
OSAS > 30 kg/m2.
In participants with OSAS, serum IL-6 levels were significantly
higher when the mean BMI of controls was ≤30 (MD = 3.16
pg/ml, P = 0.004); likewise, serum IL-6 levels were lower where
the mean BMI of controls was >30 (MD = 0.35 pg/ml, P =
0.008), and where the total sample size was ≤100 (MD = 0.93
pg/ml, P < 0.0001).
Furthermore, among those with OSAS, mean plasma IL-
6 levels were significantly higher in studies where the mean
BMI of controls ≤30 kg/m2 (MD = 0.50 pg/ml, P = 0.004),
in studies where the mean AHI of individuals with OSAS
> 30 events/h (MD = 1.38 pg/ml, P < 0.00001), and those
where the mean AHI of individuals with OSAS ≤ 30 events/h
(MD= 0.38 pg/ml, P = 0.02).
Mean BMI of OSAS Patients ≤30 kg/m2
The subgroup analysis for serum and plasma levels of IL-6 of
adults where themean BMI of individuals with OSAS≤ 30 kg/m2
is reported in Table 6.
There was significantly higher levels of serum IL-6 in
individuals with OSAS, both when controls had BMIs lower than
TABLE 5 | Subgroup analysis for serum and plasma levels of inteleukin-6 in adults where mean BMI of OSAS patients >30 kg/m2.
Subgroup analysis of serum level (n) MD (95% CI), P-value, I2 (%), Ph Subgroup analysis of plasma level (n) MD (95% CI), P-value, I
2 (%), Ph
Overall (15) 1.07 (0.63, 1.50), <0.00001, 97,
<0.00001
Overall (8) 0.96 (−1.16, 3.07), 0.38, 98,
<0.00001
Mean BMI of controls, kg/m2 Mean BMI of controls, kg/m2
>30 (11) 0.35 (0.09, 0.62), 0.008, 87,
<0.00001
>30 (4) 1.69 (−4.61, 8.00), 0.60, 99,
<0.00001
≤30 (4) 3.16 (1.00, 5.32), 0.004, 95,
<0.00001
≤30 (4) 0.50 (0.16, 0.85), 0.004, 33, 0.21
Total number of participants Total number of participants
>100 (2) 2.06 (−0.19, 4.31), 0.07, 89, 0.003 >100 (2) 0.31 (−0.09, 0.70), 0.13, 0, 0.79
≤100 (13) 0.93 (0.47, 1.39), <0.0001, 97,
<0.00001
≤100 (6) 1.41 (−2.29, 5.11), 0.45, 99,
<0.00001
Mean AHI of OSAS patients, events/h Mean AHI of OSAS patients, events/h
>30 (6) 0.23 (−0.11, 0.57), 0.18, 77, 0.0006 >30 (4) 1.38 (0.96, 1.79), <0.00001, 0, 0.53
≤30 (5) 0.89 (−0.28, 2.05), 0.14, 62, 0.03 ≤30 (3) 0.38 (0.05, 0.71), 0.02, 0, 0.78
BMI, body mass index; CI, confidence interval; OSAS, obstructive sleep apnea syndrome; MD, mean difference; Ph, Pheterogeneity .
Bold numbers show statistically significant value (P < 0.05).
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TABLE 6 | Subgroup analysis for serum and plasma levels of inteleukin-6 in adults where mean BMI of OSAS patients ≤30 kg/m2.
Subgroup analysis of serum level (n) MD (95% CI), P-value, I2 (%), Ph Subgroup analysis of plasma level (n) MD (95% CI), P-value, I
2 (%), Ph
Overall (19) 10.59 (8.64, 12.53), <0.00001, 100,
<0.00001
Overall (11) 4.20 (2.95, 5.46), <0.00001, 99,
<0.00001
Mean BMI of controls, kg/m2 Mean BMI of controls, kg/m2
>30 (1) 4.03 (2.38, 5.68), <0.00001 >30 (0) NA
≤30 (18) 11.02 (9.01, 13.04), <0.00001, 100,
<0.00001
≤30 (11) 4.10 (2.86, 5.34), <0.00001, 99,
<0.00001
Total number of participants Total number of participants
>100 (7) 11.92 (2.31, 21.52), 0.02, 100,
<0.00001
>100 (3) 0.49 (−0.08, 1.06), 0.09, 96,
<0.00001
≤100 (12) 8.59 (6.89, 10.29), <0.00001, 99,
<0.00001
≤100 (8) 7.06 (3.68, 10.44), <0.0001, 99,
<0.00001
Mean AHI of OSAS patients, events/h Mean AHI of OSAS patients, events/h
>30 (7) 18.16 (10.17, 26.15), <0.00001,
100, <0.00001
>30 (6) 8.48 (4.75, 12.21), <0.00001, 99,
<0.00001
≤30 (2) 1.05 (−0.16, 2.27), 0.09, 71, 0.06 ≤30 (4) 0.16 (−0.16, 0.48), 0.32, 68, 0.02
BMI, body mass index; CI, confidence interval; OSAS, obstructive sleep apnea syndrome; MD, mean difference; NA, not available; Ph, Pheterogeneity .
Bold numbers for statistically significant values (P < 0.05).
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30 kg/m2 (MD = 11.02 pg/ml, P < 0.00001) and when this was
higher than 30 kg/m2 (MD = 4.03 pg/ml, P < 0.00001), when
overall sample size was both <100 (MD = 8.59 pg/ml, P <
0.00001) and >100 (MD = 11.92 pg/ml, P = 0.02), and when
the mean AHI of individuals with OSAS was higher than 30 (MD
= 18.16 pg/ml, P < 0.00001).
Under the following conditions, plasma levels of IL-6 were
significantly higher: the mean BMI of controls was ≤30 kg/m2
(MD = 4.10 pg/ml, P < 0.00001), total sample size was ≤100
(MD = 7.06 pg/ml, P < 0.0001), and mean AHI of individuals
with OSAS was ≤30 events/h (MD= 8.48 pg/ml, P < 0.00001).
Meta-Regression
The results of meta-regression showed that with greater age,
serum IL-6 levels were significantly higher. The publication year,
the mean BMI, the mean AHI, and number of participants had
no independent significant effects on serum or plasma IL-6 levels
(Table 7).
Quality Assessment
The quality scores of the studies included in the meta-analysis are
reported in Table 8.
Sensitivity Analysis
The “cumulative analysis” and the “one study removed” as two
sensitivity analyses confirmed the stability of the results. In
addition, excluding studies with outlier data did not affect the
pooled analysis of serum (MD = 2.89 pg/ml, P < 0.00001) or
plasma (MD= 2.78 pg/ml, P < 0.00001) IL-6 levels (Table 9).
Publication Bias
The funnel plots of the analysis of serum and plasma IL-6 levels
are shown in Figure 6, and Table 10 gives the results of the
trim-and-fill method on bias.
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TABLE 8 | Quality assessment scores of the studies involved in the meta-analysis.
The first author, year Selection Comparability Exposure Total
points
ADULTS
Vgontzas, 1997 (26) *** – *** 6
Huiguo, 2000 (27) *** ** *** 8
Roytblat, 2000 (28) *** * *** 7
Teramoto, 2003 (29) ** – *** 5
Yokoe, 2003 (30) *** ** *** 8
Ciftci, 2004 (12) *** ** *** 8
Imagawa, 2004 (31) *** * *** 7
Ryan, 2006 (32) *** ** *** 8
de la Peña Bravo, 2007
(34)
*** ** *** 8
Harsch, 2007 (35) *** ** *** 8
Arias, 2008 (36) *** ** *** 8
Constantinidis, 2008 (37) *** * *** 7
Li, 2008 (40) **** ** *** 9
Takahashi, 2008 (41) *** ** *** 8
Tomiyama, 2008 (42) *** ** *** 8
Vgontzas, 2008 (43) *** ** *** 8
Yamamoto, 2008 (44) *** ** *** 8
Carneiro, 2009 (45) *** ** *** 8
Li, 2009 (46) *** ** *** 8
Thomopoulos, 2009 (47) *** ** *** 8
Sahlman, 2010 (48) *** ** *** 8
Steiropoulos, 2010 (49) *** ** *** 8
Ye, 2010 (50) **** ** *** 9
Liu, 2011(51) *** ** *** 8
Fornadi, 2012 (52) *** ** *** 8
Medeiros, 2012 (53) *** ** *** 8
Qian, 2012 (54) *** ** *** 8
Ye, 2012 (55) *** ** *** 8
Hargens, 2013 (56) *** ** *** 8
Kurt, 2013 (57) *** * *** 7
Yang, 2013 (58) *** ** *** 8
Ciccone, 2014 (59) *** ** *** 8
Kritikou, 2014 (61) *** ** *** 8
Unuvar Dogan, 2014 (62) *** ** *** 8
De, 2015 (63) *** ** *** 8
Gaines, 2015 (64) *** ** *** 8
Hui, 2015 (65) ** - *** 5
Ulasli, 2015 (67) *** ** *** 8
Thunstrom, 2015 (66) **** ** *** 9
Dogan, 2016 (68) *** ** *** 8
Nizam, 2016 (70) *** ** *** 8
Vicente, 2016 (71) *** ** *** 8
Hirotsu, 2017 (72) **** ** *** 9
Kong, 2017 (73) *** ** *** 8
Thorn, 2017 (74) *** ** *** 8
Weingarten, 2017 (76) *** ** *** 8
Zhang, 2017 (77) *** * *** 7
Al-Terki, 2018 (78) *** ** *** 8
(Continued)
TABLE 8 | Continued
The first author, year Selection Comparability Exposure Total
points
Bhatt, 2018 (79) *** ** *** 8
Bozic, 2018 (80) *** ** *** 8
Kong, 2018 (81) *** ** *** 8
Lu, 2018 (82) *** ** *** 8
Motamedi, 2018 (83) **** ** *** 9
Sundbom, 2018 (84) **** ** *** 9
Bhatt, 2019 (85) *** * *** 7
Tang, 2019 (86) *** ** *** 8
Galati, 2020 (87) **** ** *** 8
CHILDREN
Tam, 2006 (33) **** ** *** 9
Gozal, 2008 (38) **** ** *** 9
Li, 2008 (39) *** * *** 7
Gileles-Hillel, 2014 (60) *** ** *** 8
Huang, 2016 (69) *** * *** 7
Van Eyck, 2017 (75) *** * *** 7
Each asterisk denotes 1 point.
For serum and plasma IL-6 levels, Egger’s test (P = 0.00044
and P = 0.01445, respectively) revealed a publication bias, but
Begg’s test (P = 0.44811 and P = 0.55922, respectively) indicated
no bias either between or across the studies.
For serum IL-6 levels and 14 imputed studies, under the
fixed-effects model, the point estimate and pseudo 95% CI for
the combined studies is 0.024 (0.018, 0.030); using the trim–fill
method, the imputed point estimate is 0.023 (0.017, 0.029). In
addition, under the random-effects model, the point estimate
and 95% CI for the combined studies is 2.411 (2.076, 2.747);
using the trim–fill method, the imputed point estimate is 0.458
(0.086, 0.830).
For plasma IL-6 levels and 10 imputed studies, under the
fixed-effects model, the point estimate and 95% CI for the
combined studies is 0.252 (0.220, 0.283), and using trim–fill
method, the imputed point estimate is 0.200 (0.117, 0.231). In
addition, under the random-effects model, the point estimate and
pseudo 95% CI for the combined studies is 2.941 (1.872, 4.011);
using the trim–fill method, the imputed point estimate is 0.290
(−0.734, 1.314).
The overall effect sizes for serum and plasma IL-6 levels
reported in the forest plot appears valid, with a trivial publication
bias effect based on a fixed-effects model, because the observed
estimates were similar to the adjusted estimates. In contrast, the
overall effect sizes on serum and plasma IL-6 levels reported in
the forest plot appeared invalid, with a significant publication
bias effect based on random-effects model, because the observed
estimates were substantially different to the adjusted estimates.
DISCUSSION
The present meta-analysis with 63 studies evaluated serum
IL-6 levels (37 studies of adults and three of children) and
plasma IL-6 levels (20 studies of adults and three of children)
Frontiers in Immunology | www.frontiersin.org 13 July 2020 | Volume 11 | Article 1343
Imani et al. Interleukin and Obstructive Sleep Apnea Syndrome
TABLE 9 | Sensitivity analysis on the results of serum and plasma levels in adults.
First author, year Sample Reason for removing MD (95% CI) Z P value I2 Ph
Hargens, 2013 Serum Outlier data 2.89 (2.54, 3.24) 16.04 <0.00001 99% <0.00001
Harsch, 2007 Plasma Outlier data 2.78 (1.91, 3.66) 6.24 <0.00001 99% <0.00001
FIGURE 6 | Funnel plot of analysis of interleukin-6 levels in adult participants on (A) serum and (B) plasma in adult participants. Open circles represent observed
studies. Black circles represent imputed studies. Open diamonds represent the pooled effects from the original studies. Black diamonds represent the pooled effects
incorporating the imputed studies.
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TABLE 10 | The results of trim-and-fill method.
Sample Value Studies trimmed Fixed effects Random effects Q value
Point estimate Lower limit Upper limit Point estimate Lower limit Upper limit
Serum Observed – 0.02403 0.01818 0.02988 2.41151 2.07576 2.74726 4,869.43934
Adjusted 14 0.02287 0.01702 0.02872 0.45786 0.08567 0.83005 7,858.53130
Plasma Observed – 0.25196 0.22049 0.28343 2.94160 1.87192 4.01128 1,640.40890
Adjusted 10 0.20025 0.116914 0.23136 0.28995 −0.73377 1.31366 3,295.78126
comparing individuals with OSAS to controls. The analysis
showed that plasma and serum IL-6 levels of adults with OSAS
were significantly higher than the corresponding levels of control.
For children with OSAS, plasma IL-6 levels but not serum
IL-6 levels were significantly higher than those of controls.
The present conclusions have clinical importance because an
elevated IL-6 level can be a risk factor for the development
of cardiovascular diseases in adults with OSAS (88). These
conclusions also have practical importance because, in addition
to routine checks on sleep and sleep-disordered breathing, both
children and adults with OSAS need a thorough monitoring of
their immune systems.
One study (89) has shown that OSAS can alter the secretory
levels of several hormones. However, vascular and systemic
inflammation is the main pathogenesis of OSAS-related cardiac
metabolic processes via activation of inflammatory pathways
(90). Nadeem et al. (9) concluded, in their meta-analysis of 14
studies, that adults with OSAS had higher serum levels of IL-
6 than healthy controls. Zhong et al. (16) similarly concluded
from their meta-analysis that both children (four studies) and
adults with OSAS (31 studies) had significantly higher serum
IL-6 levels than controls. Although the exact mechanism of the
OSAS-induced impact on levels of IL-6 is not known, both
sleep deprivation and hypoxemia are believed to be important
causative factors (32).
IL-6 is the cytokine with the most clearly documented
effects on nonimmunological tissues and has been termed a
pleiotropic or “endocrine” cytokine (91). In healthy individuals,
inflammatory cytokines such as IL-6 are involved in the
regulation of physiological sleep associated with the circadian
secretion pattern (92). A good night’s sleep and a good sense of
well-being on the following day can be associated with reduced
IL-6 secretion (93), whereas increased secretion of this cytokine
can cause excessive daytime sleepiness (EDS) and fatigue (26,
94). In this respect, we note that EDS is a principal complaint
of patients with sleep disorders (95) and is one of the most
important physiological consequences of OSAS (96). In a similar
vein, a meta-analysis of studies measuring the IL-6 level of
patients with major depression found that these levels were
significantly higher than in controls (97).
Furthermore, previous studies (26, 94) have confirmed that
serum IL-6 levels are positively correlated with higher BMI
scores as a proxy for obesity. Roytblat et al. (28) evaluated
serum IL-6 levels of individuals with obesity, individuals with
OSAS, and healthy controls. They found that IL-6 levels were
34-fold higher in individuals with obesity hypoventilation than
in controls, and 8-fold higher in individuals with OSAS. In
addition, serum cytokine levels were higher in all individuals
with obesity. To explain these results, it appears that oxidative
stress, inflammation, and sympathetic activation as proxies
for pathophysiological mechanisms known to be present in
individuals with OSAS also occur in individuals with obesity
(98). The correlations between the levels of cytokines, apnea,
and obesity are unclear (63). In our meta-analysis, based on
subgroup analyses, the serum and plasma IL-6 levels in obese
participants with OSAS were very much lower than in nonobese
OSAS participants. However, some studies (26, 63, 68, 99) have
reported a positive and significant correlation between BMI and
IL-6 levels in OSAS cases, although other studies (12, 51) failed to
find any significant correlation. Therefore, the higher MD of IL-6
levels in nonobese OSAS samples found in the present analysis
may possibly indicate that BMI by itself does not affect IL-6 levels
in OSAS patients but that there are other confounding factors
influencing the serum and plasma IL-6 levels.
Next, several studies (26, 30, 66, 83) have shown that
individuals with severe OSAS have higher mean plasma/serum
IL-6 levels than either those with mild OSAS or controls.
Furthermore, higher serum IL-6 levels have been found to be
significantly correlated with higher AHI in individuals with
OSAS (r = 0.33, P = 0.03) (12). Our subgroup analysis similarly
showed that serum and plasma levels of IL-6 of individuals
with an AHI > 30 events/h was higher than the levels of
individuals with an AHI ≤ 30 events/h; this was the case in
particular for participants with a mean BMI ≤ 30 kg/m2 and
of Asian background. It follows that Asians with AHI > 30
events/h and BMI ≤ 30 kg/m2 are at the greatest risk of having
high serum IL-6 levels. The data available from the studies
included in our analysis are insufficient to clarify the meaning
of the patterns of results observed and in particular cannot shed
any direct light on the underlying physiological mechanisms.
It follows that future studies should investigate the extent to
which ethnicity and its genetic make-up might be associated
with vulnerability.
Despite the novelty of the findings, the following limitations
should be considered. First, in none of the studies were results
adjusted to reflect possible confounding factors such as obesity,
smoking, or alcohol consumption. Second, the results of the
funnel plots showed a publication bias across the studies; it
follows that a systematic bias in data presentation cannot be
ruled out. Third, the studies with small sample sizes (<100)
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had insufficient power to detect associations. Fourth, there was
a high level of heterogeneity among studies with respect to some
analyses. Fifth, studies reported different cutoff values for AHI,
making comparisons between the studies difficult. Sixth, in some
studies, level of IL-6 was treated as a secondary outcome.
In contrast, the strengths of the meta-analysis were as
follows. First, the meta-regression revealed that age could have a
confounding effect on serum results. Second, there were sufficient
studies to allow for subgroup analysis. Third, sensitivity analysis
confirmed the stability of results. Fourth, studies published in
languages other than English were included in the meta-analysis.
CONCLUSIONS
The results of the present meta-analysis showed higher levels of
IL-6 in individuals with OSAS to be related to the severity of
the disease. Furthermore, age has an impact on the associations
between OSAS and IL-6 levels. Future studies might investigate
the extent to which interventions to address OSAS (e.g., using
CPAP devices) impact positively on IL-6 levels and possibly also
on weight regulation.
PRACTICE POINTS
• Both children and adults with OSAS need careful monitoring
of their immune system, as plasma and serum IL-6
concentrations are higher than in healthy counterparts.
• This statement holds particularly true for older individuals
with OSAS and with higher BMI scores.
• Individuals with OSAS are at particular risk of suffering from
other illnesses related to an impaired immune system.
RESEARCH AGENDA
• In individuals with OSAS and receiving CPAP treatment,
IL-6 concentrations should be assessed before and after
the CPAP treatment as an indicator of a normalized
psychophysiological recovery.
• In individuals with OSAS and tonsillectomy, IL-6
concentrations should be assessed before and after the
surgical intervention as an indicator of a normalized
psychophysiological recovery.
• In individuals with OSAS and receiving appropriate treatment,
IL-6 concentrations should be associated with possible changes
in academic performance and social behavior.
• In overweight individuals with OSAS, assessment
of the family system (overweight/obese parents or
siblings) might explain why OSAS could persist in an
undetected fashion.
• Retrospective chart records should calculate the extent
to which OSAS and a deteriorated immune system
might be associated with DALYS (disability-adjusted
life years).
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